Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Royal College of Surgeons, Ireland
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05773183CT.gov Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men | — | Unknown | — | — | — |
NCT01686828CT.gov T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Undecylate (this asset) | Royal College of Surgeons, Ireland | P1/2 | CCC · 52 |
| Liraglutide | Anders Fink-Jensen, MD, DMSci | P4 | A |
| Semaglutide | Nordsjaellands Hospital | P4 | A |
| Metformin | Jinnah Sindh Medical University | P4 | BBB |
| Tirzepatide | Washington University School of Medicine | P4 | BBB |
| Pravastatin | National Human Genome Research Institute (NHGRI) | P4 | BBB |
| Midazolam | Baskent University | P4 | BB |
| Retrovir | Kirby Institute | P4 | BB |
| Hydrochlorothiazide | Vanderbilt University Medical Center | P3 | BB |
+42 more in the Metabolic Disease cohort
Other indications for Testosterone Undecylate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hypogonadotropic Hypogonadism | — | P4 | A · 82 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 73 |
| Sexual Disorder | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Undecylate in Metabolic Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-undecylate-metabolic-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →